Specialty × MAC Jurisdiction Intelligence
RheumatologyCMS & MAC AlertsNGS (National Government Services) · Jurisdictions J6, JK
Every CMS transmittal, NGS (National Government Services) LCD revision, Federal Register notice, and OIG alert affecting Rheumatology billing teams in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin. Signal-scored and updated daily.
Active alerts
11
Critical / High
4
MAC jurisdiction
J6, JK
Highest-risk CPT
CPT 99214
Recent Rheumatology alerts under NGS (National Government Services)
4 of the 11 most recent Rheumatology reimbursement alerts are Critical/High-severity for NGS (National Government Services) (Jurisdictions J6, JK) billing teams. Each links to the source CMS/MAC document with the codes to review and the action to take.
- FDA Approval: XELJANZ (TOFACITINIB) — Type 1 - New Molecular EntityJul 8, 2026
- FDA Approval: XELJANZ XR (TOFACITINIB) — Type 3 - New Dosage FormJul 8, 2026
- FDA Approval: RINVOQ (UPADACITINIB) — Type 1 - New Molecular EntityJul 8, 2026
- FDA Approval: XELJANZ (TOFACITINIB) — Type 3 - New Dosage FormJul 8, 2026
- FDA Approval: OLUMIANT (BARICITINIB) — Type 1 - New Molecular EntityJul 8, 2026
- FDA Approval: RINVOQ (UPADACITINIB) — Type 3 - New Dosage FormJul 8, 2026
- FDA Approval: EXDENSUR (DEPEMOKIMAB) — Type 1 - New Molecular EntityJun 13, 2026
- LCD L39427: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — CGSCGS Administrators · Jun 5, 2026
- LCD L39481: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — WPSWPS · Jun 5, 2026
- LCD L39467: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — NoridianNoridian · Jun 5, 2026
- LCD L39469: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — NoridianNoridian · Jun 5, 2026
Signal intelligence — Rheumatology × NGS (National Government Services)
Highest-risk CPT code
CPT 99214
Office visit, established patient, moderate complexity
View full CPT alert profileNGS (National Government Services) jurisdiction
J6, JK
Covers Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin. Every rheumatology LCD revision, CMS transmittal, and Federal Register notice affecting these states is signal-scored and surfaced here daily.
View all 11 active alerts for Rheumatology under NGS (National Government Services)
Full alert text, action recommendations, effective date deadlines, MAC LCD links, and signal score rationale — updated daily.
About NGS (National Government Services) (Jurisdictions J6, JK)
NGS (National Government Services) is the Medicare Administrative Contractor responsible for processing Medicare Part A and Part B claims in Jurisdictions J6, JK, covering Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin.NGS (National Government Services) issues Local Coverage Determinations (LCDs) that define coverage criteria, ICD-10-CM diagnosis code requirements, and CPT billing guidelines for Rheumatology procedures within its jurisdiction. CLV Intelligence monitors NGS (National Government Services)'s LCD publication feed, provider bulletin archives, and CMS contractor-specific transmittals daily.
Rheumatology alerts in other MAC jurisdictions
Get weekly Rheumatology alerts for NGS (National Government Services) — free
No credit card required. Unsubscribe any time.